all-trans-retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia

American Journal of Hematology

Volumn 70, Issue 1, 2002, Pages 39-47

  Larsen, Christian Rifbjerg ^a,b   Hansen, Per Boye ^a   Clausen, Nielsaage Tffner ^a  

^a HILLERØD HOSPITAL   (Denmark)

^b NONE   (Denmark)

Author keywords

Acute promyelocytic leukemia; all trans retinoic acid; CYP26; Metabolism; p450 enzymes

Indexed keywords

CYTOCHROME P450; LIGAND; MESSENGER RNA; OXYGENASE; RETINOIC ACID; RETINOIC ACID 4 HYDROXYLASE; RETINOIC ACID RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CANCER REGRESSION; CELL CLONE; CONTROLLED STUDY; DOSE RESPONSE; DRUG METABOLISM; DRUG SENSITIVITY; ENZYME INDUCTION; ENZYME REGULATION; ENZYME SUBSTRATE; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIGAND BINDING; MYELOID LEUKEMIA; POINT MUTATION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DOMAIN; PROTEIN EXPRESSION; RETROVIRUS;

ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; RECEPTORS, RETINOIC ACID; RNA, MESSENGER; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0036240012     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10099     Document Type: Article

References (47)

1. Chromosomal translocation t(15; 17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML
2. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia
3. PMLRAR homodimers: Distinct DNA binding properties and heteromeric interactions with RXR
4. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid
5. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)
6. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells
7. A decade of molecular biology of retinoic acid receptors
8. The retinoid receptors
9. Binding of 9-cis-retinoic acid and all-trans-retinoic acid to retinoic acid receptors alpha, beta, and gamma. Retinoic acid receptor gamma binds all-trans-retinoic acid preferentially over 9-cis-retinoic acid
10. all-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results
11. Effect of all-transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial
12. Continuous treatment with all-trans-retinoic acid causes a progressive reduction in plasma drug concentrations: Implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia
13. Retinoid resistance in acute promyelocytic leukemia: New mechanisms, strategies, and implications
14. Therapy of acute promyelocytic leukemia: All-transretinoic acid and beyond
15. Acute promyelocytic leukemia: A curable disease
16. Pharmacokinetics of oral all-trans-retinoic acid in patients with acute promyelocytic leukemia
17. Resistance to all-transretinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells
18. Clinical pharmacology of oral all-trans-retinoic acid in patients with acute promyelocytic leukemia
19. Clinical pharmacology of all-trans-retinoic acid
20. In vitro all-trans-retinoic acid (ATRA) sensitivity and cellular retinoic acid binding protein (CRABP) levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia
21. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans-retinoic acid in acute promyelocytic leukemia
22. Mechanisms of retinoid resistance in leukemic cells: Possible role of cytochrome P450 and P-glycoprotein
23. ATRA (ouble) in treatment of acute promyelocytic leukemia
24. Metabolism in vivo of all-trans-retinoic acid
25. Interactions of retinoid binding proteins and enzymes in retinoid metabolism
26. Recent advances in the in vivo and in vitro metabolism of retinoic acid
27. CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family
28. Identification of the retinoic acid-inducible all-trans-retinoic acid 4-hydroxylase
29. cDNA cloning of human retinoic acid-metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450
30. Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for alltrans-RA and can be induced through RA receptors in human breast and colon carcinoma cells
31. Mouse P450RAI (CYP26) expression and retinoic acid-inducible retinoic acid metabolism in F9 cells are regulated by retinoic acid receptor gamma and retinoid X receptor alpha
32. Retinoic acid receptors regulate expression of retinoic acid 4-hydroxylase that specifically inactivates all-trans-retinoic acid in human keratinocyte HaCaT cells
33. N-4-Hydroxyphenylretinamide enhances retinoic acid-induced differentiation and retinoylation of proteins in the human acute promyelocytic leukemia cell line, NB4, by a mechanism that may involve inhibition of retinoic acid catabolism
34. Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity
35. Inhibition of Grb2 and Crk1 proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells
36. Metabolism of vitamin A and its active metabolite all-trans-retinoic acid in small intestinal enterocytes
37. Differential uptake of all-trans-retinoic acid by acute promyelocytic leukemic cells: Evidence for its role in retinoic acid efficacy
38. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans-retinoic acid and intensive chemotherapy
39. Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation
40. all-trans-retinoic acid (ATRA) induces expression of cytochrome P450RAI (CYP26AI) in human intestinal, liver and promyelocytic leukemia cells: A potential mechanism contributing to increased ATRA metabolism and resistance
41. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells
42. Activation of retinoid receptors RAR alpha and RXR alpha induces differentiation and apoptosis, respectively, in HL-60 cells
43. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
44. Cytochrome P450RAI (CYP26) promoter: A distinct composite retinoic acid response element underlies the complex regulation of retinoic acid metabolism
45. Liposomal all-trans-retinoic acid (ATRA) in treatment of acute promyelocytic leukemia
46. Relapsed acute promyelocytic leukemia previously treated with all-trans-retinoic acid: Clinical experience with a new synthetic retinoid, Am-80
47. Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule